Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.
Hulshof EC, Deenen MJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Touw DJ, van der Weide J, van Westrhenen R, Deneer VHM, Guchelaar HJ, Swen JJ. Hulshof EC, et al. Eur J Hum Genet. 2023 Sep;31(9):1088-1089. doi: 10.1038/s41431-023-01315-x. Eur J Hum Genet. 2023. PMID: 36797469 Free article. No abstract available.
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.
Hulshof EC, Deenen MJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Touw DJ, van der Weide J, van Westrhenen R, Deneer VHM, Guchelaar HJ, Swen JJ. Hulshof EC, et al. Eur J Hum Genet. 2023 Sep;31(9):982-987. doi: 10.1038/s41431-022-01243-2. Epub 2022 Nov 28. Eur J Hum Genet. 2023. PMID: 36443464 Review.
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
Hulshof EC, de With M, Creemers GJ, Guchelaar HJ, Mathijssen RH, Gelderblom H, Deenen MJ. Hulshof EC, et al. Eur J Cancer. 2022 Sep;172:231-233. doi: 10.1016/j.ejca.2022.05.045. Epub 2022 Jul 3. Eur J Cancer. 2022. PMID: 35793611 No abstract available.
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ. Hulshof EC, et al. Eur J Cancer. 2022 Feb;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 5. Eur J Cancer. 2022. PMID: 34998046 Free article.
Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
Hulshof EC, Lurvink RJ, Caserta N, de Hingh IHJT, van Wezel T, Böhringer S, Swen JJ, Gelderblom H, Guchelaar HJ, Deenen MJ. Hulshof EC, et al. Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1925-1931. doi: 10.1016/j.ejso.2020.04.019. Epub 2020 Apr 15. Eur J Surg Oncol. 2020. PMID: 32354538
Taurolidine in Pediatric Home Parenteral Nutrition Patients.
Hulshof EC, Hanff LM, Olieman J, de Vette S, Driessen GJ, Meeussen C, Escher JC. Hulshof EC, et al. Pediatr Infect Dis J. 2017 Feb;36(2):233-235. doi: 10.1097/INF.0000000000001404. Pediatr Infect Dis J. 2017. PMID: 27846059